Apellis Pharmaceuticals, Inc.

MA · United States · Reporting entity ID 100000931823

Total reported 2019–2025

$55.1M

#160 of 2,960 reporting companies — 0.1% of all reported industry payments

$14.0M in general payments across 31,801 records, plus $41.2M in research funding across 6,261 records.

How it breaks down

General payments $13,970,628

Research funding $41,169,164

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.